No Data
KEYMED BIO-B: 2024 ANNUAL REPORT
Express News | KeyMed Biosciences Announces Approval of Ind for Cm518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers
The Innovative Drugs Concept is generally rising, INNOVENT BIO (01801) increased by 7%. Institutions indicate that the actual geopolitical risks in the Sector are relatively low.
Jinwu Financial News | The Innovative Drugs sector generally rose, with Hutchmed (China) (00013) up by 3.92%. The company will announce data at the American Association for Cancer Research (AACR) 2025 annual meeting. In addition, AKESO (09926) rose by 7.1%, INNOVENT BIO (01801) rose by 7%, SKB BIO-B (06990) rose by 4.76%, KEYMED BIO-B (02162) rose by 3.41%, and 3SBIO (01530) rose by 3.28%. Sinolink's Research Reports stated that the rapidly changing external tariff environment provides the pharmaceutical sector with good anti-risk capabilities and growth potential.
With the "self-immunization drug king" tightening the pressure, how did KEYMED BIO-B (02162) achieve a maximum stock price increase of over 80% in three months?
According to Kanuoya's disclosed 2024 Earnings Reports, the company's revenue for the period was 0.428 billion yuan, a 21% increase compared to last year; gross profit was 0.416 billion yuan, a 31% increase from last year; and the annual loss was 0.515 billion yuan, a 44% increase year-on-year.
[Brokerage Focus] Sinolink: The actual geopolitical risk in the Innovative Drugs Sector is low. In the second half of the year, it is recommended to focus on left-side reversals.
Jinwu Finance | Sinolink's Research Reports indicate that the external tariff environment is changing rapidly, and the pharmaceutical Sector has good risk resistance and growth potential. The geopolitical risk in the Innovative Drugs Sector is very low, and there are opportunities for domestic substitution in Blood Products, Medical Device, and instruments. A reversal in the left-side Sector is imminent after the first quarter report, and attention is recommended. The firm states that in the second half of the year, attention should be given to the left-side reversal, as performance gradually recovers and the fundamentals improve. Focus on the individual stocks in Generic Drugs, chain pharmacies, Medical Device, and Traditional Chinese Medicine that are experiencing difficulties. Throughout the year, it is advised to continuously focus on the main line of Innovative Drugs and semi-Innovative Drugs; additionally, in the short term, attention should be paid to the fluctuations in tariffs regarding Blood Product
Guosen: Focus on the Innovative Drugs that are accelerating their overseas expansion and the service Sector supported by policies.
Guosen recommends paying attention to the Medical Services Sector.
